Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-21R drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-21R ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL21R Products |
| Gene Delivery | IL-21R Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL21R Products |
| Benchmark Ab | Anti-IL-21R (Sequence of ATR-107) Recombinant positive control. |
View IL21R Products |
| Validator | IL-21R siRNA Set For knockdown verification. |
View IL21R Products |
| Related Target A | IL-21 The primary ligand for IL-21R, crucial for ligand-blocking and functional assay development. |
View IL21 Products |
| Related Target B | IL2RG The common gamma chain (CD132) that heterodimerizes with IL-21R to initiate downstream JAK/STAT signaling. |
View IL2RG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species cross-reactivity evaluation (Human vs. Cynomolgus) | Human and Cynomolgus IL-21R ortholog proteins available with >95% purity verified by SDS-PAGE |
| Receptor heterodimerization screening | High-purity IL-21R and IL2RG (common gamma chain) proteins available for complex assembly assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IL-21R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-21R therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and cytokine-fusion proteins. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective modulation of the IL-21/IL-21R pathway to balance efficacy and systemic toxicity in autoimmune diseases and oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Bristol Myers Squibb, Novo Nordisk | Autoimmune Diseases (SLE, RA, Sjögren's) | Ligand-blocking assays (Need high-purity IL-21R ECD-Fc and active IL-21 ligand) |
| Bispecific / Multi-specific | Roche, Sanofi | Oncology (Combination Immunotherapy) | Dual-targeting binding validation (Need cross-reactive antigens) |
| Cytokine-Fusion Proteins (Agonists) | Amgen, Innovent | Solid Tumors, Hematological Malignancies | Receptor activation and signaling assays (Need Lentivirus for stable cell lines) |